Skip to main content
GutCited

Fermented milk containing Bifidobacterium lactis DN-173 010 in childhood constipation: a randomized, double-blind, controlled trial.

Merit M Tabbers, Ania Chmielewska, Maaike G Roseboom, Nolwenn Crastes, Catherine Perrin et al.
RCT Pediatrics 2011 101 citations

Study Design

Study Type
Randomized Controlled Trial
Sample Size
80
Duration
3.0 weeks
Intervention
Fermented milk containing Bifidobacterium lactis DN-173 010 in childhood constipation: a randomized, double-blind, controlled trial.
Comparator
control group
Primary Outcome
the change in stool frequency from baseline to after 3 weeks of product consumpt
Effect Direction
Mixed
Risk of Bias
Moderate

Abstract

BACKGROUND: Constipation is a frustrating symptom affecting 3% of children worldwide. A fermented dairy product containing Bifidobacterium lactis strain DN-173 010 was effective in increasing stool frequency in constipated women. Our aim was to assess the effects of this product in constipated children. METHODS: In this prospective randomized, double-blind, controlled trial, 159 constipated children (defecation frequency < 3 times per week) were randomly allocated to receive either a fermented dairy product that contains B lactis DN-173 010 (n = 79) or a control product (n = 80) twice a day for 3 weeks. The primary endpoint was the change in stool frequency from baseline to after 3 weeks of product consumption. Analyses were by intention to treat. RESULTS: Eleven children did not return to any follow-up visit (5 in the probiotic group, 6 in the control group) and were therefore excluded from the final analysis. Thus, 74 children in each group were analyzed. The change in stool frequency from baseline to after 3 weeks of product consumption increased in both groups, but the difference was not statistically significant (2.9 ± 3.2 in probiotic group versus 2.6 ± 2.6 in control group, P = .35). There were no serious adverse events. CONCLUSIONS: In constipated children, the fermented dairy product containing B lactis strain DN-173 010 did increase stool frequency, but this increase was comparable in the control group. There is currently not sufficient evidence to recommend fermented dairy products containing B lactis strain DN-173 010 in this category of patients. Future studies should focus on whether a longer period of probiotic products is more effective in children who have a short history of constipation.

TL;DR

There is currently not sufficient evidence to recommend fermented dairy products containing B lactis strain DN-173 010 in this category of patients, and future studies should focus on whether a longer period of probiotic products is more effective in children who have a short history of constipation.

Used In Evidence Reviews

Similar Papers

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.